Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RUA. Repositorio Institucional de la Universidad de Alicante
Publication Otros (Other)

Engineering Proteins for PEDOT Dispersions: A New Horizon for Highly Mixed Ionic-Electronic Biocompatible Conducting Materials

  • Dominguez-Alfaro, Antonio
  • Casado, Nerea
  • Fernandez, Maxence
  • Garcia-Esnaola, Andrea
  • Calvo, Javier
  • Mantione, Daniele
  • Calvo, M. Reyes
  • Cortajarena, Aitziber L.
Poly (3,4-ethylenedioxythiophene) (PEDOT) doped with polystyrene sulfonate (PSS) is the most used conducting polymer from energy to biomedical applications. Despite its exceptional properties, there is a need for developing new materials that can improve some of its inherent limitations, e.g., biocompatibility. In this context, doping PEDOT is propose with a robust recombinant protein with tunable properties, the consensus tetratricopeptide repeated protein (CTPR). The doping consists of an oxidative polymerization, where the PEDOT chains are stabilized by the negative charges of the CTPR protein. CTPR proteins are evaluated with three different lengths (3, 10, and 20 identical CTPR units) and optimized varied synthetic conditions. These findings revealed higher doping rate and oxidized state of the PEDOT chains when doped with the smallest scaffold (CTPR3). These PEDOT:CTPR hybrids possess ionic and electronic conductivity. Notably, PEDOT:CTPR3 displayed an electronic conductivity of 0.016 S cm−1, higher than any other reported protein-doped PEDOT. This result places PEDOT:CTPR3 at the level of PEDOT-biopolymer hybrids, and brings it closer in performance to PEDOT:PSS gold standard. Furthermore, PEDOT:CTPR3 dispersion is successfully optimized for inkjet printing, preserving its electroactivity properties after printing. This approach opens the door to the use of these novel hybrids for bioelectronics.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Multiparametric modulation of magnetic transduction for biomolecular sensing in liquids

  • Sanz-de-Diego, Elena
  • Aires, Antonio
  • Palacios-Alonso, Pablo
  • Cabrera, David
  • Silvestri, Niccolo
  • Vequi-Suplicy, Cinthia C.
  • Artés-Ibáñez, Emilio J.
  • Requejo-Isidro, José
  • Delgado-Buscalioni, Rafael
  • Pellegrino, Teresa
  • Cortajarena, Aitziber L.
  • Terán, Francisco J.
Electronic supplementary information (ESI) available. See DOI: https://doi.org/ 10.1039/d3nr06489a, The recent COVID19 pandemic has remarkably boosted the research on in vitro diagnosis assays to detect biomarkers in biological fluids. Specificity and sensitivity are mandatory for diagnostic kits aiming to reach clinical stages. Whilst the modulation of sensitivity can significantly improve the detection of biomarkers in liquids, this has been scarcely explored. Here, we report on the proof of concept and parametrization of a novel biosensing methodology based on the changes of AC magnetic hysteresis areas observed for magnetic nanoparticles following biomolecular recognition in liquids. Several parameters are shown to significantly modulate the transducing capacity of magnetic nanoparticles to detect analytes dispersed in saline buffer at concentrations of clinical relevance. Magnetic nanoparticles were bio-conjugated with an engineered recognition peptide as a receptor. Analytes are engineered tetratricopeptide binding domains fused to the fluorescent protein whose dimerization state allows mono- or divalent variants. Our results unveil that the number of receptors per particle, analyte valency and concentration, nanoparticle composition and concentration, and field conditions play a key role in the formation of assemblies driven by biomolecular recognition. Consequently, all these parameters modulate the nanoparticle transduction capacity. Our study provides essential insights into the potential of AC magnetometry for customizing biomarker detection in liquids., This work was partially funded by the Spanish State Research Agency (PCI2019-103600, CEX2020-001039-S, MDM-2017-0720, PID2019-111649RB-I00, PID2020-117080RB-C51, PID2020- 117080RB-C53, PID2019-111649RB-I00, PDC2021-120957-I00, PDC2022-133345-I00, and Hipernano, RED2018-102626-T, PTA2018-015076) and Comunidad de Madrid (PEJ-2017-AI/ BMD-7517, PEJ-2020-AI/IND-19394, NANOMAGCOST S2018/ NMT-4321). COST Actions CA17115 (MyWave) and CA17140 (Nano2Clinic) were also acknowledged. This work was partially supported by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie HeatnMof grant (GA No. 860942)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cardiac fibrosis inhibitor CTPR390 prevents structural and morphological changes in human engineered cardiac connective tissue

  • Maestro, David
  • Palanca, Ana R.
  • Soto, Helena
  • Llanera, I.
  • DeGrave, Alisa Nicole
  • Guedes, Gabriela
  • Oliveira, Guilherme Henrique de
  • Coelho Conceição, André Luiz
  • Mieites, Verónica
  • Icardo, Jose M.
  • Sánchez-Cano, Carlos
  • Conde, Olga M.
  • Lutz, Susanne
  • Cortajarena, Aitziber L.
  • Villar Ramos, Ana V.
Cardiac fibrosis is a key characteristic of heart failure. CTPR390, an experimental anti-fibrotic inhibitor targeting Hsp90, has shown success in animal models, but remains unexplored in human cardiac models. This study evaluated an engineered cardiac connective tissue (ECCT) model, focusing on changes in the extracellular matrix and fibroblasts. Results showed that CTPR390 prevented architectural changes in TGFβ1-activated ECCT, preserving tissue perimeter, collagen fibers alignment while reducing structured areas and degree of collagen structuration. CTPR390 treatment reduced cell area of fibroblasts under tension, without changes in the internal rounded cells devoid of tension. Fibroblast recruitment to tension areas was diminished, showing biomechanical behavior similar to control ECCT. This treatment also lowered the gene and protein expression of key pro-fibrotic markers. Here, advanced biotechnology was employed to detect the detailed structure of tissue fibrosis reduction after administering CTPR390, representing a significant advancement toward clinical application for cardiac fibrosis treatment., This work was partially supported by Agencia Estatal de Investigación (AEI/MCI/10.13039/501100011033), Spain. A.V.V. PID2021-125702OB-I00. Fomento de la transferencia de conocimiento en la Comunidad Autónoma de Cantabria SUBVTC-2023-0006 T. A.L.C. acknowledges support by the Agencia Estatal de Investigación Grant PDC2021-120957-I00-NanoIVD and PDC2022-133345-I00-ProIMAGE funded by MCIN/AEI/10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR” and Grant PID2022-137977OB-I00-ProTher funded by MCIN/AEI/ 10.13039/501100011033. C.S.C. thanks Gipuzkoa Foru Aldundia (Gipuzkoa Fellows program) Grant number 2019-FELL-000018-01/62/2019 for financial support. G.G. thanks the financial support of “la Caixa” Foundation (ID100010434, fellowship: LCF/BQ/DI20/11780020). This work was performed under the Maria de Maeztu Units of Excellence and Severo Ochoa Centers Programs from the Spanish State Research Agency – Grants No. MDM-2017-0720 (CIC biomaGUNE) and CEX2018-000867-S (DIPC). O.M.C. and V.M. thank the AEI for the infrastructure EQC 2019-006589-P and the PREVAL 21/07 grant from IDIVAL., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2018-000867-S)., Peer reviewed